Literature DB >> 14694300

Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.

John G Kral1, Swan N Thung, Simon Biron, Frederic-Simon Hould, Stefane Lebel, Simon Marceau, Serge Simard, Picard Marceau.   

Abstract

BACKGROUND: Both weight loss and gastrointestinal surgery for obesity can cause liver disease, making their role in the treatment of obesity-related liver disease controversial.
METHODS: Six hundred eighty-nine severely obese women (n=551) and men (n=138), BMI=47+/-9 kg.m(-2) (mean+/-SD), without known liver disease, underwent biliopancreatic diversion (BPD) with liver biopsy. Fourteen patients (2%) had cryptogenic cirrhosis, 11 of whom underwent multiple repeat biopsies. After 38+/-18 kg weight loss, 104 of the 689 patients underwent routine second biopsies during reoperations 41+/-25 months after BPD. All biopsy specimens were graded for steatosis, fibrosis, and inflammation by a blinded hepatopathologist.
RESULTS: All 689 patients lost weight accompanied by improvements in the metabolic syndrome. Among the 104 patients who underwent reoperation, severe fibrosis (grade 3-5) decreased in 28 whereas mild fibrosis (grade 1-2) appeared in 42. Increased fibrosis was related to low-normal serum albumin, uncontrolled diarrhea, low intake of alcohol, and menopausal status. Fibrosis and inflammation decreased over time (P<.01). The 11 patients with cirrhosis exhibited decreased fibrosis from a mean grade 5 to grade 3, as well as reduced inflammation, Mallory bodies, and glycogenated nuclei. Seven patients had disappearance and 2 regression of nodules and fibrous bridging.
CONCLUSIONS: The metabolic syndrome of obesity is a determinant of liver fibrosis and cirrhosis, treatable by substantial weight loss after malabsorptive surgery.

Entities:  

Mesh:

Year:  2004        PMID: 14694300     DOI: 10.1016/j.surg.2003.10.003

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  77 in total

1.  Outcomes of Bariatric Surgery in Patients with Cirrhosis.

Authors:  Inka Miñambres; Miguel Angel Rubio; Ana de Hollanda; Irene Breton; Nuria Vilarrasa; Silvia Pellitero; Marta Bueno; Albert Lecube; Clara Marcuello; Albert Goday; Maria D Ballesteros; German Soriano; Assumpta Caixàs
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

2.  Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.

Authors:  Palanivelu Praveenraj; Rachel M Gomes; Saravana Kumar; Purushothaman Karthikeyan; Annapoorni Shankar; Ramakrishnan Parthasarathi; Palanisamy Senthilnathan; Subbiah Rajapandian; Chinnusamy Palanivelu
Journal:  Obes Surg       Date:  2015-11       Impact factor: 4.129

3.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

4.  Modified jejunoileal bypass surgery with biliary diversion for morbid obesity and changes in liver histology during follow-up.

Authors:  Iraj Fazel; Akram Pourshams; Shahin Merat; Roya Hemayati; Masoud Sotoudeh; Reza Malekzadeh
Journal:  J Gastrointest Surg       Date:  2007-08       Impact factor: 3.452

Review 5.  Benefits of lifestyle modification in NAFLD.

Authors:  Stephen A Harrison; Christopher Paul Day
Journal:  Gut       Date:  2007-10-02       Impact factor: 23.059

6.  Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage.

Authors:  Edoardo G Giannini; Claudia Coppo; Chiara Romana; Giovanni B Camerini; Franco De Cian; Nicola Scopinaro; Francesco S Papadia
Journal:  Dig Dis Sci       Date:  2018-04-09       Impact factor: 3.199

Review 7.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology.

Authors:  Guy Bower; Tania Toma; Leanne Harling; Long R Jiao; Evangelos Efthimiou; Ara Darzi; Thanos Athanasiou; Hutan Ashrafian
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

8.  Resolution of diabetes mellitus and metabolic syndrome following Roux-en-Y gastric bypass and a variant of biliopancreatic diversion in patients with morbid obesity.

Authors:  Theodore K Alexandrides; George Skroubis; Fotis Kalfarentzos
Journal:  Obes Surg       Date:  2007-02       Impact factor: 4.129

9.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Aynur Unalp; Cynthia E Behling; Joel E Lavine; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

Review 10.  The metabolic syndrome and nonalcoholic fatty liver disease in children.

Authors:  Shikha S Sundaram; Phil Zeitler; Kristen Nadeau
Journal:  Curr Opin Pediatr       Date:  2009-08       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.